Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the ...
March 24 2014 - 5:05AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs in the infectious disease field, today
announced eight studies have been accepted for presentation at the
International Liver Congress (ILC), which is the 49th Annual
Meeting of the European Association for the Study of the Liver
(EASL) taking place in London April 9-12, 2014. These presentations
will report results of regimens containing ABT-450, Enanta’s lead
protease inhibitor for hepatitis C virus (HCV) identified in its
ongoing collaboration with AbbVie. Abstracts can now be viewed at
the EASL website at www.easl.eu.
Following is a list of ABT-450-related presentations:
Oral Presentations:
- SAPPHIRE-II: Phase 3 Placebo-Controlled
Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267,
ABT-333 and Ribavirin in Treatment-Experienced Adults with
Hepatitis C Virus in Genotype-1S. Zeuzem, et al., April 10, 2014,
14:00-14:15 BST
- Results from the Phase 2 PEARL-I Study:
Interferon-Free Regimens of ABT-450/r + ABT-267 with or without
Ribavirin in Patients with HCV Genotype 4 InfectionC. Hezode, et
al., April 11, 2014, 09:45-10:00 BST
- SAPPHIRE-I: Phase 3 Placebo-Controlled
Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ ABT-267,
ABT-333 and Ribavirin in 631 Treatment-Naïve Adults with Hepatitis
C Virus in Genotype-1JJ Feld, et al., April 11, 2014, 10:15-10:30
BST
- Results of the Phase 2 Study of
M12-999: Interferon-Free Regimen of ABT-450/r/ABT-267+ABT-333+
Ribavirin in Liver Transplant Recipients with Recurrent HCV
Genotype 1 InfectionP. Kwo, et al., April 12, 10:15-10:30 BST
Poster Presentations:
- P783 – Serum MIR-122 May Serve as a
Biomarker for Response to Direct Acting Antivirals: Effect of
ABT-450/r with ABT-333 or ABT-267 on MIR-122 in HCV-Infected
SubjectsJ.F. Waring, et al., April 11, 2014, 09:00 – 18:00 BST
- P1230 – Lack of Impact of Baseline
Resistance- Associated Variants (RAVS) on Treatment Outcome in the
Aviator Study with ABT-450/r, ABT-333, and ABT-267 +/- RibavirinP.
Krishnan, et al., April 12, 2014, 09:00 – 18:00 BST
Late-Breaker Oral Presentation:
- TURQUOISE-II: SVR12 Rates of 92%-96% in
380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated
Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin
(3D+RBV)F. Poordad, et al. April 12, 2014, 15:30-15:45 BST
Late-Breaker Poster Presentation:
- P# 1299 – PEARL-III: 12 Weeks of
ABT-450/r/267 + ABT-333 Achieved SVR in >99% of 410
Treatment-Naïve HCV Genotype 1b-Infected Adults With or Without
RibavirinP. Ferenci, et al. April 12, 2014, 09:00-18:00 BST
About ABT-450
ABT-450 is an NS3 protease inhibitor discovered through Enanta’s
collaboration with AbbVie. AbbVie and Enanta have an agreement to
collaborate on the discovery, development and commercialization of
HCV NS3 and NS3/4A protease inhibitors. Protease inhibitors play an
essential role in the viral life cycle of the hepatitis C virus
(HCV). Inhibition of the protease prevents non-structural (NS)
proteins from forming and thereby prevents replication and survival
of the HCV virus. ABT-450 is part of AbbVie’s investigational
regimen for HCV that consists of boosted protease inhibitor
ABT-450/ritonavir (referred to as ABT-450/r), NS5A inhibitor
ABT-267 and non-nucleoside polymerase inhibitor ABT-333.
About Hepatitis C Virus (HCV)
Hepatitis C is a liver disease affecting over 170 million people
worldwide. The virus is typically spread through direct contact
with the blood of an infected person. Hepatitis C increases a
person’s risk of developing chronic liver disease, cirrhosis, liver
cancer and death. Patients with compensated cirrhosis have a liver
that is heavily scarred but that can still perform many important
bodily functions with few or no symptoms. There is an acute need
for new HCV therapies that are safer and more effective for many
variants of the virus.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs in the infectious disease field. Enanta is discovering, and
in some cases developing, novel inhibitors designed for use against
the hepatitis C virus (HCV). These inhibitors include members of
the direct acting antiviral (DAA) inhibitor classes – protease
(partnered with AbbVie), NS5A (partnered with Novartis) and
nucleotide polymerase – as well as a host-targeted antiviral (HTA)
inhibitor class targeted against cyclophilin. Additionally, Enanta
has created a new class of antibiotics, called Bicyclolides, for
the treatment of multi-drug resistant bacteria, with a focus on
developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus)
infections.
InvestorsEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMediaMacDougall Biomedical
CommunicationsKari Watson, 781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024